The pandemic taught the biopharma industry many lessons, including just how vital R&D productivity is to ensure the health and well-being of our local and global communities. This session showcased how the SAS Viya platform is a productivity multiplier for both data scientists and clinical scientists, how SAS advanced analytics enables deeper insights and accelerates discovery, and how the open design of the SAS platform allows integration with your current workflow and the technologies you depend on. The session featured various innovative projects led by the SAS analytics Center of Excellence using SAS Viya to accelerate drug discovery, enable computational drug repurposing at the Food and Drug Administration, and support the development of personalized therapeutics in collaboration with the University of North Carolina and the Rapidly Emerging Antiviral Drug Development Initiative (READDI). The hosts held a fireside chat with a leading virologist who is applying SAS in the race to discover novel antivirals in preparation for the next pandemic. This industry session will also highlighted how the SAS Viya platform operationalizes AI-driven analytics with maximal transparency and reproducibility, ensuring results are trusted by scientists, regulators and, most importantly, patients.
Presentation slides are attached to this post.
Rachel Hardin, SAS
Hamza Ghadyali, SAS
Nat Moorman, READDI
